1. Home
  2. PRG vs URGN Comparison

PRG vs URGN Comparison

Compare PRG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$34.14

Market Cap

1.3B

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$29.61

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
URGN
Founded
2020
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
PRG
URGN
Price
$34.14
$29.61
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$50.00
$29.29
AVG Volume (30 Days)
429.7K
931.0K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
0.89
N/A
Revenue
$2,409,223,000.00
$1,128,000.00
Revenue This Year
$23.77
$129.09
Revenue Next Year
$7.91
$70.96
P/E Ratio
$37.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.80
$3.42
52 Week High
$41.14
$32.37

Technical Indicators

Market Signals
Indicator
PRG
URGN
Relative Strength Index (RSI) 53.45 66.69
Support Level $32.07 $17.86
Resistance Level $34.43 $30.00
Average True Range (ATR) 1.60 1.97
MACD -0.13 0.51
Stochastic Oscillator 65.20 71.93

Price Performance

Historical Comparison
PRG
URGN

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: